QPPV.COM KNOWLEDGE ASSESSMENT

Sacubitril: Discovery, Development, Safety and Pharmacovigilance โ€” Knowledge Assessment

Test your understanding of the concepts covered by Sacubitril: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient receiving sacubitril/valsartan develops hyperkalaemia and a change in kidney function during an intercurrent illness. Which approach is most appropriate?
Question 2 of 10 When assessing a suspected angioedema event following a switch from an ACE inhibitor, which information is especially relevant?
Question 3 of 10 A report describes facial swelling after sacubitril/valsartan use, but provides no detail on the affected site or clinical findings. What is the best next step?
Question 4 of 10 Which conclusion is most appropriate for the primary PARAGON-HF analysis?
Question 5 of 10 A patient is being switched from an ACE inhibitor to sacubitril/valsartan. Which statement best reflects the EU safety precaution described in the article?
Question 6 of 10 A patient develops symptomatic hypotension after an up-titration. Which follow-up information would best support a medically informed assessment?
Question 7 of 10 A report attributes a reduction in cardiovascular death in PARADIGM-HF specifically to sacubitril monotherapy. What is the most appropriate scientific interpretation?
Question 8 of 10 A series of reports shows renal changes after treatment initiation, but many patients also had heart failure and were taking other medicines. What is the most defensible interpretation?
Question 9 of 10 A trial report describes a 200 mg twice-daily combination dose, while the product information lists a tablet strength of 97 mg/103 mg. What is the best interpretation?
Question 10 of 10 How should the PARADIGM-HF run-in period affect interpretation of the trial's results for routine clinical practice?

Select an answer to continue.

QPPV.com